Switzerland’s Roche is buying UK-based Tusk Therapeutics in a deal that could hit EUR 655 million.
Johnson & Johnson and Geron had teamed up to develop and commercialize imetelstat, a first-in-class telomerase inhibitor, for myelofibrosis and myelodysplastic syndromes.
Brooks Automation will increase the automation and cryogenics specialist’s toehold in the life sciences industry with a $450 million all-cash acquisition of genomic services group Genewiz.
Shares of OncoMed Pharmaceuticals fell after the company announced that Celgene walked away from a deal to license the bispecific antibody navicixizumab.
Amicus Therapeutics inked a definitive agreement for 10 gene therapy programs licensed from Nationwide Children’s Hospital through the acquisition of Celenex.
Shares of Molecular Templates were up more than 52 percent after announcing a deal with Takeda that could be worth up to $632 million to develop CD38-targeted engineered toxin bodies.
MannKind Corp. and United Therapeutics Corp. signed a worldwide exclusive license and collaboration deal to develop and commercialize a dry powder formulation of treprostinil being studied in clinical trials to treat pulmonary arterial hypertension.
Emergent BioSolutions will buy privately held Adapt Pharma, beefing up its portfolio with Narcan, the only FDA-approved needle-free emergency opioid overdose treatment.
Collaboration partners Evotec AG and Haplogen GmbH announced that Haplogen will enter into a multi-year drug discovery and development deal with Bayer AG to focus on pulmonary diseases.